with similar benefit irrespective of the
timing of GpIIb-IIIa antagonist use.
Again, as in the overall per-protocol
population, the degree of benefit of clopidogrel
pretreatment among patients receiving
and not receiving GpIIb-IIIa inhibitors
appeared to be influenced by the
timing of pretreatment